Mutations, Biomarkers, and Pathways: A Molecular Tour of Gastrointestinal Cancer

This lecture offers the following credit types: CME, P.A.C.E.®, Florida
 

This presentation will provide an overview of key molecular biomarkers that play a crucial role in the diagnosis, prognosis, and treatment of colon, gastric, and esophageal cancers. It will explore the latest advancements in biomarker discovery, highlighting their clinical utility. Attendees will gain insights into the molecular pathways driving these cancers and the implications of biomarkers such as microsatellite instability, HER2, and PD-L1 in guiding treatment decisions and improving patient outcomes.

Originally published on February 4, 2026

Lecture Presenter

Cameron Beech, MD

Cameron Beech, MD

Assistant Professor (Clinical)
Spencer Fox Eccles School of Medicine at the University of Utah
Medical Director
Solid Tumor Molecular Oncology, ARUP Laboratories

Dr. Cameron Beech is a medical director of Solid Tumor Molecular Oncology at ARUP Laboratories, and an assistant professor (clinical) for the Spencer Fox Eccles School of Medicine at the University of Utah. He received his medical degree from the University of Toledo College of Medicine and did his residency in anatomic and clinical pathology at Yale New Haven Hospital. He completed fellowships in oncologic surgical pathology and molecular genetic pathology at Memorial Sloan Kettering Cancer Center and gastrointestinal, pancreatic, and hepatobiliary pathology at Yale New Haven Hospital. Dr. Beech is board certified in anatomic and clinical pathology and molecular genetic pathology by the American Board of Pathology. His research interests include application of next generation sequencing to solid tumors and genomic alteration in gastrointestinal malignancies.

Objectives

After this presentation, participants will be able to:

  • Identify key molecular biomarkers associated with colon, gastric, and esophageal cancers and their clinical significance
  • Explain the role of molecular biomarkers in the prognosis and therapeutic management of gastrointestinal cancers
  • Discuss the latest advancements in biomarker-driven targeted therapies and personalized medicine approaches for colon, gastric and esophageal cancer
  • Illustrate the molecular pathways involved in the pathogenesis of colon, gastric, and esophageal cancers and their implications for biomarker development

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories